lonafarnib has been researched along with Adverse Drug Event in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deterding, K; Wedemeyer, H | 1 |
| Ai Thanda Han, M; Bishop, R; Canini, L; Cooper, SL; Cotler, SJ; Dahari, H; Glenn, JS; Haynes-Williams, V; Heller, T; Idilman, R; Keskin, O; Kleiner, DE; Koh, C; Pinto, P; Subramanya, G; Uprichard, SL; Winters, MA; Wolff, EF; Yurdaydin, C; Zhao, X | 1 |
1 review(s) available for lonafarnib and Adverse Drug Event
| Article | Year |
|---|---|
Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Drug-Related Side Effects and Adverse Reactions; Hepatitis B, Chronic; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Nucleic Acids; Piperidines; Polymers; Pyridines; Recurrence; Treatment Outcome | 2019 |
1 trial(s) available for lonafarnib and Adverse Drug Event
| Article | Year |
|---|---|
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Male; Middle Aged; Piperidines; Placebos; Plasma; Prenylation; Pyridines; RNA, Viral; Treatment Outcome; Viral Load | 2015 |